Payment overview · 2025
General Payments
$507.65
28 reported records · 12 companies
Healthcare provider profile · identity verified
Charles Gregory Cooper, P.A.
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · BROWNWOOD, TX · NPI 1477543734
Verified facts
What the public records show
CMS Open Payments records show Charles Gregory Cooper, P.A. received $507.65 in general payments during 2025 across 28 reported records.
Amgen Inc. accounted for 28.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 179 claims for Mounjaro by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Wegovy by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $142.51 | 28.1% | 9 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $70.65 | 13.9% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $51.07 | 10.1% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $38.23 | 7.5% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $37.26 | 7.3% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $33.56 | 6.6% | 2 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $31.87 | 6.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $29.95 | 5.9% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $27.06 | 5.3% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $16.30 | 3.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.35 | 3.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.84 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $507.65 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $96.13 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $70.65 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $51.07 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $51.07 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $46.38 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $46.38 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $38.23 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $38.23 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $33.56 | 2 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $31.87 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $29.95 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $27.06 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $21.19 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $16.30 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.07 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.35 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.35 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 35 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 132 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 179 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 155 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
35 | 19 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
132 | 42 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
132 | 42 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
179 | 29 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
30 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
155 | 39 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 339 | 140 |
| Levothyroxine Sodium | Levothyroxine Sodium | 283 | 97 |
| Metoprolol Succinate | Metoprolol Succinate | 251 | 94 |
| Losartan Potassium | Losartan Potassium | 216 | 75 |
| Omeprazole | Omeprazole | 188 | 70 |
| Mounjaro | Tirzepatide | 179 | 29 |
| Gabapentin | Gabapentin | 170 | 77 |
| Ozempic | Semaglutide | 155 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 155 | 72 |
| Amlodipine Besylate | Amlodipine Besylate | 139 | 50 |
| Jardiance | Empagliflozin | 132 | 42 |
| Spironolactone | Spironolactone | 126 | 54 |
| Lisinopril | Lisinopril | 124 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 118 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 116 | 56 |
| Tramadol Hcl | Tramadol Hcl | 115 | 44 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 107 | 93 |
| Carvedilol | Carvedilol | 105 | 44 |
| Ondansetron Odt | Ondansetron | 105 | 42 |
| Cefdinir | Cefdinir | 95 | 84 |
| Trazodone Hcl | Trazodone Hcl | 93 | 42 |
| Pregabalin | Pregabalin | 92 | 25 |
| Fluconazole | Fluconazole | 91 | 49 |
| Doxycycline Hyclate | Doxycycline Hyclate | 83 | 73 |
| Metformin Hcl Er | Metformin Hcl | 83 | 38 |
| Ropinirole Hcl | Ropinirole Hcl | 78 | 24 |
| Furosemide | Furosemide | 76 | 38 |
| Allopurinol | Allopurinol | 70 | 26 |
| Famotidine | Famotidine | 70 | 31 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 69 | 37 |
| Ezetimibe | Ezetimibe | 69 | 34 |
| Dexamethasone | Dexamethasone | 65 | 58 |
| Duloxetine Hcl | Duloxetine Hcl | 63 | 18 |
| Potassium Chloride | Potassium Chloride | 61 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 60 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 58 | 34 |
| Eszopiclone | Eszopiclone | 57 | 11 |
| Azithromycin | Azithromycin | 56 | 47 |
| Estradiol | Estradiol | 53 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 52 | 29 |
| Eliquis | Apixaban | 47 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 47 | 18 |
| Donepezil Hcl | Donepezil Hcl | 45 | 16 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 45 | 44 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 45 | 13 |
| Sertraline Hcl | Sertraline Hcl | 45 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 44 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 42 | suppressed |
| Alprazolam | Alprazolam | 41 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 41 | 19 |
| Metformin Hcl | Metformin Hcl | 41 | 17 |
| Methocarbamol | Methocarbamol | 40 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 38 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 37 | 12 |
| Bupropion Xl | Bupropion Hcl | 36 | 13 |
| Glimepiride | Glimepiride | 36 | 13 |
| Farxiga | Dapagliflozin Propanediol | 35 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | 18 |
| Finasteride | Finasteride | 33 | 12 |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Clonazepam | Clonazepam | 31 | 15 |
| Entresto | Sacubitril/Valsartan | 30 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | 20 |
| Memantine Hcl | Memantine Hcl | 29 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 27 | 14 |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 27 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Prednisone | Prednisone | 25 | 23 |
| Buspirone Hcl | Buspirone Hcl | 24 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 24 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Modafinil | Modafinil | 22 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 20 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Lactulose | Lactulose | 19 | 14 |
| Meloxicam | Meloxicam | 19 | 12 |
| Repatha Sureclick | Evolocumab | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | 11 |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | 14 |
| Lorazepam | Lorazepam | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Belsomra | Suvorexant | 15 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 15 | 15 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 15 | suppressed |
| Guanfacine Hcl Er | Guanfacine Hcl | 15 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 14 | suppressed |
| Simvastatin | Simvastatin | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Amoxicillin | Amoxicillin | 11 | 11 |
| Celecoxib | Celecoxib | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Progesterone | Progesterone, Micronized | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Wegovy | Semaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $507.65 · 28 records | Amgen Inc. | Cologuard Collection Kit, Dexcom G6 Transmitter, FARXIGA, JARDIANCE, KRYSTEXXA, Kerendia, LEQVIO, MOUNJARO, OTEZLA, Ozempic, PURIFIED CORTROPHIN GEL, QULIPTA, REPATHA, Rybelsus, The Cologuard Plus Collection Kit, UBRELVY, Veozah, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error